KRAS and lung carcinoma: In spite of the above-cited success, major challenges remain concerning treatment of lung cancer, such as targeting the “undruggable” oncogenic drivers, such as mutant KRAS, or understanding why responses to molecular targeted therapies in NSCLC are almost always incomplete and transient.